NurExone Advances ExoPTEN Manufacturing for First-in-Human Studies in Spinal Cord and Optic Nerve Injuries
Key Insights
NurExone Biologic has initiated evaluation of Israeli production partners for small-scale GMP manufacturing of ExoPTEN, its lead exosome-based therapy for central nervous system injuries.
New scientific data demonstrates that NurExone's exosomes show significantly higher CD73 (search)-associated biological activity compared to commercially available controls, with statistically significant differences (p < 0.01).
The company is preparing for potential first-in-human use programs targeting acute spinal cord injury and optic nerve injury, pending regulatory approval.
NurExone Biologic Inc (search). has taken a significant step toward clinical development by initiating the evaluation of Israeli manufacturing partners for small-scale Good Manufacturing Practices (GMP) production of ExoPTEN, its lead exosome-based therapy for central nervous system injuries. The preclinical biotechnology company announced this manufacturing milestone as part of its strategy to prepare for future first-in-human studies targeting acute spinal cord injury and optic nerve injury.
Manufacturing Strategy Positions Company for Clinical Transition
The company is currently evaluating several Israeli manufacturing organizations with expertise in advanced biologics and GMP-aligned systems for small-scale ExoPTEN manufacturing runs. Dr. Ina Sarel, Head of CMC, Quality and Regulatory Affairs, described this as "a strategically important next phase of operational de-risking," noting that Israel will serve as the starting point for small-scale GMP production and process validation before transitioning to the United States for scale-up.
Dr. Lior Shaltiel, Chief Executive Officer, emphasized the therapeutic potential of the approach: "ExoPTEN brings together a powerful synergistic impact with highly active exosomes produced, combined with a targeted siRNA. As we advance our manufacturing plans, small clinical grade batches will position us to prepare a First-in-Human use submission in the future, if and when the regulatory pathway supports it."
The company clarified that no compassionate-use or clinical manufacturing is being initiated at this stage, with all such activities subject to regulatory engagement and approval.
Superior Biological Activity Demonstrated in New Data
Recent analytical testing has provided compelling evidence for the potency of NurExone's exosome platform. The company's exosomes, produced from human bone marrow-derived mesenchymal stem cells (MSC), demonstrated significantly higher CD73 (search)-associated biological activity compared with commercially available MSC exosome controls. CD73 is a surface enzyme linked to extracellular signaling and tissue-repair mechanisms.
The average of NurExone's two manufacturing batches showed meaningfully higher adenosine monophosphate (AMP) to adenosine conversion per particle compared with the control. The difference was statistically significant (t-test, p < 0.01), indicating that NurExone's exosomes possess stronger functional characteristics associated with regenerative potential, or what the company describes as stronger "healing" or "anti-inflammatory" signals.
These findings validate the potency of NurExone's therapeutic exosomes and strengthen the biological rationale for their use as a delivery vehicle in ExoPTEN. The results also demonstrate the high quality of the Master Cell Bank acquired by NurExone and the effectiveness of the company's patented 3D shear-force production technology.
Targeting Multi-Billion Dollar Markets
ExoPTEN is being developed for both acute spinal cord injury and optic nerve injury, which represent multi-billion-dollar markets. The company has not yet determined which indication will be prioritized for the first-in-human program. The therapy has already achieved important regulatory milestones, including obtaining Orphan Drug Designation, which facilitates the roadmap toward clinical trials in the U.S. and Europe.
NurExone's approach combines exosome-based delivery with targeted siRNA technology, positioning the company in the growing field of regenerative medicine for central nervous system injuries. The company has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
Strategic Communications Partnership
Subject to TSX Venture Exchange approval, NurExone has engaged Russo Partners LLC, a New York-based strategic communications firm, for an initial consulting project for up to two months for a fixed fee of US$6,600. The engagement reflects the company's preparation for increased visibility as it advances toward clinical development.